PT - JOURNAL ARTICLE AU - YUKI KOBARI AU - KAZUHIKO YOSHIDA AU - JUNPEI IIZUKA AU - TSUNENORI KONDO AU - HIDEKI ISHIDA AU - KAZUNARI TANABE AU - TOSHIO TAKAGI TI - Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma AID - 10.21873/invivo.12663 DP - 2021 Nov 01 TA - In Vivo PG - 3585--3589 VI - 35 IP - 6 4099 - http://iv.iiarjournals.org/content/35/6/3585.short 4100 - http://iv.iiarjournals.org/content/35/6/3585.full SO - In Vivo2021 Nov 01; 35 AB - Background: Although the CheckMate 214 trial affirmed the effectiveness of nivolumab–ipilimumab combination therapy in advanced or metastatic renal cell carcinoma (mRCC), its safety and efficacy in patients with end-stage renal disease (ESRD) on haemodialysis remains unexplored. Case Report: All patients were male and underwent mRCC treatment with partial nephrectomy or nephrectomy. They had ESRD and were undergoing haemodialysis. Cases 1 and 2 showed lymph node and lung metastases after initial surgery and received nivolumab–ipilimumab therapy. Case 1 had grade 3 adrenal insufficiency after four courses, which was controlled with steroids. Case 2 did not experience adverse events. Both were well controlled with complete (CR) or partial response (PR). Case 3 suffered local recurrence after nephrectomy and received combination therapy. Grade 3 adrenal insufficiency occurred following three courses, and tumour size did not change remarkably. Conclusion: Nivolumab–ipilimumab combination therapy can effectively treat mRCC patients with ESRD undergoing haemodialysis.